Your browser doesn't support javascript.
loading
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw, Amber; Panou, Vasiliki; Szejniuk, Weronika Maria; Meristoudis, Christos; Chai, Siaw Ming; van Vliet, Chris; Lee, Y C Gary; Dick, Ian M; Firth, Tina; Lynggaard, Louise Andersen; Asghari, Azadeh Birbaneh; Vyberg, Mogens; Hansen, Johnni; Creaney, Jenette; Røe, Oluf Dimitri.
Afiliación
  • Louw A; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of We
  • Panou V; Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark; Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Szejniuk WM; Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
  • Meristoudis C; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark.
  • Chai SM; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia.
  • van Vliet C; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia.
  • Lee YCG; Institute for Respiratory Health, Perth, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia; Medical School, University of Western Australia, Perth, Australia.
  • Dick IM; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia.
  • Firth T; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia.
  • Lynggaard LA; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark.
  • Asghari AB; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark.
  • Vyberg M; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
  • Hansen J; Danish Cancer Society, Research Center, Copenhagen, Denmark.
  • Creaney J; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia. Electronic address: jenette.creaney@uwa.edu.au.
  • Røe OD; Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway; Department of Clini
J Thorac Oncol ; 17(7): 921-930, 2022 07.
Article en En | MEDLINE | ID: mdl-35489694
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article